We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content. Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.
(Mayo Clinic) May 28, 2020 - Carfilzomib, a proteasome inhibitor used in combination with Lenalidomide, an immune modulating drug, is not superior to Bortezomib, Lenalidomide and Dexamethasone, in the initial treatment of multiple myeloma according to the results of phase 3 clinical trial presented today at #ASCO20 scientific program by Shaji Kumar, M.D. , a hematologist at Mayo Clinic.
(City of Hope) May 30, 2020 - A targeted therapy for colorectal cancer and an immunotherapy drug for head and neck cancer are just some of the innovative treatments City of Hope doctors are presenting at this year’s ASCO20 Virtual Scientific Program, which starts today and ends May 31.
(Pfizer) May 29, 2020 - As announced today by the Austrian Breast & Colorectal Cancer Study Group and the Alliance Foundation Trials, LLC, Pfizer Inc. reports that following a preplanned efficacy and futility analysis, the independent Data Monitoring Committee (DMC) of the collaborative Phase 3 early breast cancer PALbociclib CoLlaborative Adjuvant Study (PALLAS) determined that the trial is unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival (iDFS). Patients currently receiving palbociclib in the study will be advised about next steps by their physicians and long-term follow up of all patients will proceed as planned. No unexpected new safety signals were observed in patients receiving palbociclib.
(AstraZeneca) May 29, 2020 - Data presented at ASCO showed patients treated with a single, priming dose of tremelimumab plus Imfinzi achieved longest median survival among regimens tested.
(Bloomberg) May 29, 2020 - Biotechnology stocks saw broad swings Friday morning as investors worked their way through a deluge of data from cancer drug developers presenting at the American Society of Clinical Oncology’s virtual annual meeting.
(Lilly) May 29, 2020 - Eli Lilly and Company today announced that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA® (ramucirumab injection, 10 mg/mL solution), in combination with erlotinib, for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. With this approval, CYRAMZA has now received six FDA approvals to treat certain types of lung, liver, stomach and colorectal cancers.
(ImmunoGen) May 29, 2020 - ImmunoGen, Inc. today announced initial data from the FORWARD II study evaluating mirvetuximab soravtansine in combination with Avastin® (bevacizumab) in patients with medium and high folate receptor alpha (FRα)-expressing recurrent ovarian cancer for whom a non-platinum based combination regimen is appropriate.
(Adaptimmune) May 29, 2020 - New Phase 2 trial in EGJ cancer planned for 1H 2021, after first two patients treated responded to next-generation ADP-A2M4CD8 therapy. Durability and efficacy data presented at ASCO support potential for SPEARHEAD-1 as a registrational trial for sarcoma - commercial launch planned in the US in 2022.
(Arvinas) May 29, 2020 - Clear efficacy signal with two ongoing confirmed PSA responses, including one associated with a confirmed RECIST response.
(Pfizer) May 29, 2020 - Data simultaneously published in the New England Journal of Medicine and presented during the virtual scientific program of the 2020 ASCO Annual Meeting. Pfizer Inc. and Astellas Pharma Inc. have announced final results from the overall survival (OS) analysis of the Phase 3 PROSPER trial, which evaluated XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) versus placebo plus ADT in men with non-metastatic castration-resistant prostate cancer (nmCRPC).